

November 14, 2022

To,  
The Manager,  
Dept. of Corporate Services,  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400001

Dear Sir/Madam,

**Subject : Un-Audited Financial Results for the quarter and half-year ended September 30, 2022**  
**Reference : Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015**  
**Scrip : 511509**

With reference to the above cited subject and our letter dated October 29, 2022, we bring to your kind notice that the Board of Directors of the Company at their meeting held today, i.e. **Monday, November 14, 2022**, *inter-alia*, considered and approved the Un-Audited Standalone and Consolidated Financial Results for the quarter and half-year ended September 30, 2022.


The meeting commenced at 05.00 PM and concluded at 06.30 PM.

This is for your information and records.

Thanking you,

Yours faithfully,

For Vivo Bio Tech Limited

  
Jyotika Aasat  
Company Secretary



Encl: As above

**Vivo Bio Tech Ltd.**  
Your Drug Discovery Partner

Vivo Bio Tech Limited  
8-2-672/5&6, Ilyas Mohammed Khan Estate, 3rd Floor,  
Road No.1, Banjara Hills, Hyderabad-500034, Telangana  
E-mail:investors@vivo.bio.com CIN: L65993TG1987PLC007163

**UN-AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30TH SEPTEMBER, 2022**

S.No.	PARTICULARS	QUARTER ENDED				HALF YEAR ENDED		YEAR ENDED
		30.09.2022	30.06.2022	30.09.2021	30.09.2021	30.09.2021	31.03.2022	
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited	
I	Revenue from operations	1,253.84	1,126.33	1,017.45	2,380.17	2,316.54	5,139.10	
II	Other Income	0.59	0.09	2.39	0.68	24.47	9.21	
III	<b>Total Income</b>	<b>1,254.43</b>	<b>1,126.42</b>	<b>1,019.84</b>	<b>2,380.85</b>	<b>2,341.01</b>	<b>5,148.31</b>	
IV	<b>Expenses</b>							
	a) Increase/(decrease) in stock in trade and WIP	111.58	-52.83	-186.01	58.75	15.71	346.52	
	b) Consumption of Raw materials	89.27	134.85	233.98	224.12	365.36	797.28	
	c) Purchase of traded goods	329.41	312.98	203.44	642.39	422.58	942.19	
	d) Employees Cost	236.79	233.47	173.86	470.26	352.57	744.08	
	e) Depreciation and amortisation	179.09	176.26	106.38	355.35	192.35	399.33	
	f) Finance Cost	257.32	253.05	381.61	510.37	667.40	1,471.53	
	g) Administrative Expenditure	1,203.45	1,057.79	913.24	2,261.23	2,015.97	4,700.92	
	<b>Total</b>	<b>50.98</b>	<b>68.63</b>	<b>106.60</b>	<b>119.62</b>	<b>325.04</b>	<b>447.39</b>	
V	Profit Before Tax & Exceptional Items (III-IV)							
	Exceptional Item	50.98	68.63	106.60	119.62	325.04	447.39	
VI	<b>Profit Before Tax</b>							
VII	Tax Expense	8.51	11.46	30.30	19.97	80.88	75.85	
	a. Current Tax	30.55	25.57	48.59	56.12	93.13	151.22	
	b. Deferred tax	39.05	37.03	78.89	76.08	174.01	227.06	
	<b>Total Tax Expense</b>	<b>11.92</b>	<b>31.61</b>	<b>27.71</b>	<b>43.53</b>	<b>151.03</b>	<b>220.33</b>	
VIII	<b>Net Profit After Tax (V-VI)</b>							
	Other Comprehensive Income							
	a. Items that will be reclassified to profit or loss (Net of Tax)							
IX	<b>Total other Comprehensive Income (VII+VIII+IX)</b>	<b>11.92</b>	<b>31.61</b>	<b>27.71</b>	<b>43.53</b>	<b>151.03</b>	<b>220.33</b>	
X	<b>Paid Up Share Capital (Face value of Rs.10/-) (In lakh Units)</b>	<b>1475.86</b>	<b>1,487.65</b>	<b>1,420.45</b>	<b>1475.86</b>	<b>1,420.45</b>	<b>1,426.35</b>	
XI	<b>Earnings per equity share:</b>							
	1) Basic	0.08	0.22	0.20	0.29	1.06	1.56	
	2) Diluted	0.08	0.22	0.19	0.29	1.02	1.56	

Place: Hyderabad  
Date: 14/11/2022

For Vivo Bio Tech Limited



*M. Kalyan Ram*  
M. Kalyan Ram  
Whole Time Director  
DIN:02012580



**Vivo Bio Tech Ltd.**  
Your Drug Discovery Partner

Vivo Bio Tech Limited  
8-2-672/5&6, Ilyas Mohammed Khan Estate, 3rd Floor,  
Road No.1, Banjara Hills, Hyderabad-500034, Telangana  
E-mail:investors@vivobio.com CIN: L65993TG1987PLC007163

UN-AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30TH SEPTEMBER, 2022

Rs. in Lacs

S.No.	PARTICULARS	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
		30.09.2022 Un-Audited	30.06.2022 Un-Audited	30.09.2021 Un-Audited	30.09.2022 Un-Audited	30.09.2021 Un-Audited	31.03.2022 Audited
I	Revenue from operations	1,267.26	1,126.33	1016.83	2,393.59	2316.54	5139.10
II	Other Income	0.59	0.09	3.01	0.68	25.09	9.83
III	<b>Total Income</b>	<b>1,267.85</b>	<b>1,126.42</b>	<b>1,019.84</b>	<b>2,394.27</b>	<b>2,341.63</b>	<b>5,148.93</b>
IV	<b>Expenses</b>						
	a) Increase/(decrease) in stock in trade and WIP	111.58	-52.83	-115.67	58.75	15.71	346.52
	b) Consumption of Raw materials	0.00	-	0.00	-	0.00	-
	c) Purchase of traded goods	89.27	134.85	163.63	224.12	365.36	797.28
	d) Employees Cost	342.55	312.98	203.44	655.53	422.58	942.19
	e) Depreciation and amortisation	236.79	233.47	66.77	470.26	352.57	744.65
	f) Finance Cost	179.09	176.26	106.38	355.35	192.35	399.33
	g)Administrative Expenditure	257.45	253.05	488.70	510.50	667.40	1471.74
	<b>Total</b>	<b>1,216.72</b>	<b>1,057.79</b>	<b>913.24</b>	<b>2,274.50</b>	<b>2,015.97</b>	<b>4,701.70</b>
V	Profit Before Tax & Exceptional Item (III-IV)	51.13	68.63	106.60	119.77	325.66	447.23
VI	Exceptional Item	-	-	0.00	-	0.00	-
VII	Profit Before Tax	51.13	68.63	106.60	119.77	325.66	447.23
	Tax Expense						
	a. Current Tax	8.54	11.46	30.30	20.00	80.88	75.85
	b. Deferred tax	30.55	25.57	48.59	56.12	93.13	151.22
	<b>Total Tax Expense</b>	<b>39.08</b>	<b>37.03</b>	<b>78.89</b>	<b>76.11</b>	<b>174.01</b>	<b>227.07</b>
	<b>Net Profit After Tax (V-VI)</b>	<b>12.05</b>	<b>31.60</b>	<b>27.71</b>	<b>43.66</b>	<b>151.65</b>	<b>220.16</b>
VIII	Minority Interest	-	-	-	-	-	-
IX	Other Comprehensive Income						
	a. Items that will be reclassified to profit or loss (Net of Tax)						
X	<b>Total other Comprehensive Income(VII+VIII+IX)</b>	<b>12.05</b>	<b>31.60</b>	<b>27.71</b>	<b>43.66</b>	<b>151.65</b>	<b>220.16</b>
XI	Paid Up Share Capital (Face value of Rs.10/-) (In lakh Units)	1475.86	1,487.65	1420.45	1475.86	1420.45	1426.35
XII	<b>Earnings per equity share:</b>						
	1)Basic	0.08	0.22	0.20	0.30	1.07	1.56
	2)Diluted	0.08	0.22	0.19	0.30	1.02	1.56



For Vivo Bio Tech Limited

M. Kalyan Ram  
Whole Time Director  
DIN:02012580

Place: Hyderabad  
Date: 14/11/2022

Vivo Bio Tech Limited  
8-2-672/5&6, Ilyas Mohammed Khan Estate, 3rd Floor,  
Road No.1, Banjara Hills, Hyderabad-500034, Telangana  
E-mail:investors@vivobio.com CIN: L65993TG1987PLC007163

**Vivo Bio Tech Ltd.**  
Your Drug Discovery Partner


STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER, 2022

		Rs. In Lacs			
S.No.	Particulars	Standalone		Consolidated	
		30.09.2022	31.03.2022	30.09.2022	31.03.2022
		Un-Audited	Audited	Un-Audited	Audited
I	<b>ASSETS</b>				
	<b>Non-Current Assets</b>				
	<b>Fixed Assets</b>				
	Property, Plant and Equipment	7,661.16	7,818.64	7,997.18	8,154.67
	Capital Work-In-Progress	179.52	86.64	179.52	86.64
	Intangible Assets	1,214.18	1,362.36	1,214.18	1,362.36
	<b>Financial Assets</b>				
	Non-Current Investments	4.00	4.00	-	-
	Long Term Loans and Advances	40.34	40.34	41.71	41.71
	Other Non Current Assets				
	Deferred Tax Asset				
	<b>Total Non-Current Assets</b>	<b>9,099.20</b>	<b>9,311.98</b>	<b>9,432.58</b>	<b>9,645.37</b>
	<b>Current Assets</b>				
	Inventories	922.46	981.20	922.46	981.20
	<b>Financial Assets</b>				
	Trade Receivables	1,207.73	1,202.43	1,207.73	1,202.43
	Cash and cash equivalents	164.25	146.63	200.44	171.35
	Short term loans and advances	446.90	298.46	298.69	159.25
	Other current assets	171.39	88.92	171.66	88.92
	<b>Total Current Assets</b>	<b>2,912.72</b>	<b>2,717.65</b>	<b>2,800.97</b>	<b>2,603.16</b>
	<b>TOTAL ASSETS</b>	<b>12,011.92</b>	<b>12,029.63</b>	<b>12,233.55</b>	<b>12,248.54</b>
II	<b>EQUITY AND LIABILITIES</b>				
	<b>Equity</b>				
	Equity Share Capital	1,487.65	1,426.35	1,487.65	1,426.35
	Other Equity	3,477.25	3,219.17	3,475.71	3,099.27
	Money Received Against Share Warrants		68.96		68.96
	<b>Total Equity</b>	<b>4,964.90</b>	<b>4,714.48</b>	<b>4,963.37</b>	<b>4,594.59</b>
	<b>Liabilities</b>				
	<b>Non Current liabilities</b>				
	<b>Financial Liabilities</b>				
	Borrowings	4,473.37	4,787.71	4,696.01	5,007.83
	Long term provisions	57.23	55.42	57.23	55.42
	Deferred Tax Liabilities	210.47	154.36	210.47	154.36
	<b>Total Non Current Liabilities</b>	<b>4,741.08</b>	<b>4,997.50</b>	<b>4,963.72</b>	<b>5,217.62</b>
	<b>Current Liabilities</b>				
	<b>Financial Liabilities</b>				
	Borrowings	1,776.45	1,736.04	1,776.45	1,736.04
	Trade Payable & Other Current Liabilities	158.65	231.61	158.65	231.61
	Provisions	370.84	350.01	371.37	468.68
	<b>Total Current Liabilities</b>	<b>2,305.93</b>	<b>2,317.66</b>	<b>2,306.47</b>	<b>2,436.33</b>
	<b>TOTAL EQUITY &amp; LIABILITIES</b>	<b>12,011.92</b>	<b>12,029.63</b>	<b>12,233.55</b>	<b>12,248.54</b>

Place: Hyderabad  
Date: 14/11/2022

For Vivo Bio Tech Limited

M. Kalyan Ram  
Whole Time Director  
DIN:02012580





Vivo Bio Tech Limited  
 8-2-672/5&6, Ilyas Mohammed Khan Estate, 3rd Floor,  
 Road No.1, Banjara Hills, Hyderabad-500034, Telangana  
 E-mail:investors@vivobio.com CIN: L65993TG1987PLC007163

**Vivo Bio Tech Ltd.**  
 Your Drug Discovery Partner


STANDALONE CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2022

Particulars		Rs. In Lacs		
		As at	As at	As at
		30.09.2022	30.09.2021	31.03.2022
		Un-Audited	Un-Audited	Audited
<b>A.</b>	<b>Cash Flow from Operating Activities:</b>			
	Net Profit/ (Loss) before taxation and extraordinary items	119.62	325.04	447.00
	<b>Adjustments for:</b>			
	Depreciation	470.26	352.57	744.00
	Amortised Expenses		-	-
	Interest expenses	355.35	192.35	399.00
	Operating Profit before Working Capital Changes	<b>945.22</b>	<b>869.96</b>	<b>1,591.00</b>
	<b>Working Capital Changes</b>			
	Trade and other receivables Including Inventory	-177.45	-474.84	105.00
	Trade and Other payables	46.20	-87.58	293.00
	<b>Cash Generated from Operations</b>	<b>813.97</b>	<b>307.54</b>	<b>1,989.00</b>
	Interest paid	355.35	192.35	399.00
	Taxation for the year	76.08	174.01	227.00
	<b>Net Cash from Operating Activities</b>	<b>382.55</b>	<b>-58.82</b>	<b>1,362.00</b>
<b>B.</b>	<b>Cash Flow from Investing Activities:</b>			
	Purchase of Fixed Assets	-257.47	-93.55	-5,111.00
	Investment	0.00	-	-
	<b>Net Cash used in Investing Activities</b>	<b>-257.47</b>	<b>-93.55</b>	<b>-5,111.00</b>
<b>C.</b>	<b>Cash Flow From Financial Activities:</b>			
	Proceeds from Equity Shares	206.89	234.06	240.00
	Net Proceeds from Long Term Borrowings	-314.34	-51.56	3,545.00
	<b>Net Cash used in Financing Activities</b>	<b>-107.46</b>	<b>182.50</b>	<b>3,785.00</b>
	<b>Net increase in cash and cash equivalents</b>	<b>17.62</b>	<b>30.14</b>	<b>37.00</b>
	Cash and Cash equivalents as at Beginning of the period	147.00	109.71	110.00
	<b>Cash and Cash equivalents as at the end of the period</b>	<b>164.62</b>	<b>139.85</b>	<b>147.00</b>

Place: Hyderabad  
 Date: 14/11/2022

For Vivo Bio Tech Limited

*M. Kalyan Ram*  
 M. Kalyan Ram  
 Whole Time Director  
 DIN:02012580





Vivo Bio Tech Limited  
 8-2-672/5&6, Ilyas Mohammed Khan Estate, 3rd Floor,  
 Road No.1, Banjara Hills, Hyderabad-500034, Telangana  
 E-mail:investors@vivobio.com CIN: L65993TG1987PLC007163

**Vivo Bio Tech Ltd.**  
 Your Drug Discovery Partner


**CONSOLIDATED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2022**

Particulars		Rs. In Lacs		
		As at	As at	As at
		30.09.2022	30.09.2021	31.03.2022
		Un-Audited	Un-Audited	Audited
<b>A.</b>	<b>Cash Flow from Operating Activities:</b>			
	Net Profit/ (Loss) before taxation and extraordinary items	119.77	325.66	447.00
	<b>Adjustments for:</b>			
	Depreciation	470.26	352.57	745.00
	Amortised Expenses		-	-
	Interest expenses	355.35	192.35	399.00
	Operating Profit before Working Capital Changes	<b>945.38</b>	<b>870.57</b>	<b>1,591.00</b>
	<b>Working Capital Changes</b>			
	Trade and other receivables Including Inventory	-168.72	-474.84	125.00
	Trade and Other payables	46.29	-87.58	411.00
	<b>Cash Generated from Operations</b>	<b>822.95</b>	<b>308.16</b>	<b>2,128.00</b>
	Interest paid	355.35	192.35	399.00
	Taxation for the year	76.11	174.01	227.00
	<b>Net Cash from Operating Activities</b>	<b>391.49</b>	<b>-58.20</b>	<b>1,501.00</b>
<b>B.</b>	<b>Cash Flow from Investing Activities:</b>			
	Purchase of Fixed Assets	-257.47	-93.55	-5,111.00
	Investment	0.00	-	-
	<b>Net Cash used in Investing Activities</b>	<b>-257.47</b>	<b>-93.55</b>	<b>-5,111.00</b>
<b>C.</b>	<b>Cash Flow From Financial Activities:</b>			
	Proceeds from Equity Shares	206.89	234.06	122.00
	Net Proceeds from Long Term Borrowings	-311.82	-51.56	3,543.00
	<b>Net Cash used in Financing Activities</b>	<b>-104.94</b>	<b>182.50</b>	<b>3,665.00</b>
	<b>Net increase in cash and cash equivalents</b>	<b>29.08</b>	<b>30.76</b>	<b>55.00</b>
	Cash and Cash equivalents as at Beginning of the period	171.00	116.54	117.00
	Cash and Cash equivalents as at the end of the period	200.08	147.30	171.00

Place: Hyderabad  
 Date: 14/11/2022

For Vivo Bio Tech Limited

*M. Kalyan Ram*  
 M. Kalyan Ram  
 Whole Time Director  
 DIN:02012580





**Notes:**

1. The above Un-Audited Financial Results for the Quarter and Half year ended September 30, 2022, were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on November 14, 2022. These results have been subjected to limited review carried out by the Statutory Auditors.
2. The above Un-Audited Financial Results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of Companies Act, 2013 ('The Act') read with relevant rules issued thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
3. The Consolidated Results include results of all subsidiaries, viz., Vivobio Labs Private Limited, Vivobio Discovery Services Private Limited, Surlogic Life Consultancy Private Limited and Vivobio Consulting Services Private Limited (Formerly Donakanti Consulting Services Private Limited).
4. The Company operates in single Segments Viz., Bio Technology. Hence segmental reporting is not required.
5. The above financial results are available on the stock exchange website [www.bseindia.com](http://www.bseindia.com) and company's website [www.virinchi.com](http://www.virinchi.com).
6. Previous year's/period's figures are rearranged/ regrouped wherever necessary.

**Date: November 14, 2022**  
**Place: Hyderabad**

**For Vivo Bio Tech Limited**



**Kalyan Ram Mangipudi**  
**Whole Time Director**  
**DIN: 02012580**





**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.pmurali.com



**Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Review report to  
The Board of Directors  
Vivo Bio Tech Limited**

We have reviewed the accompanying statement of unaudited standalone financial results of **M/s. Vivo Bio Tech Limited** (the "Company") for the quarter ended 30 September, 2022 and for the period from 01 April 2022 to 30 September 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ('Ind AS 34,') prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.pmurali.com

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS 34 prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.  
Chartered Accountants  
FRN: 007257S



M V Joshi  
Partner  
M.No. 024784  
UDIN: 22024784BDBUNZ8478

Place: Hyderabad  
Date: 14.11.2022.



**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.pmurali.com


Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended

Review report to  
The Board of Directors  
Vivo Bio Tech Limited

We have reviewed the accompanying statement of unaudited consolidated financial results of M/s. **Vivo Bio Tech Limited** (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), for the quarter ended 30 September, 2022 and for the period from 01 April 2022 to 30 September 2022 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.







**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.pmurali.com

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities:

1. Vivo Bio Labs Private Limited
2. Vivo Bio Discovery Services Private Limited
3. Surlogic Life Consultancy Private Limited
4. Vivo Bio Consulting Services Private Limited (Formerly known as Donakanti Consultancy Services Private Limited)

Based on our review conducted and procedures performed as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.  
Chartered Accountants  
FRN: 007257S

M V Joshi  
Partner

M.No. 024784

UDIN: 22024784BDBWOZ5912



Place: Hyderabad

Date: 14.11.2022.